专业监测看板

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

药物 / 成分：Tremelimumab、Durvalumab

登记的停止原因（原文）：Criteria not met for second stage at time of interim analysis

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

药物 / 成分：Durvalumab (MEDI 4736)、Radiotherapy

登记的停止原因（原文）：Low accrual

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

药物 / 成分：F18 Florbetapir (amyvid) cardiac PET/CT imaging

登记的停止原因（原文）：slow recruitment.

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

药物 / 成分：Continuous infusion high-dose MCI-186、Continuous infusion low-dose MCI-186、Continuous infusion placebo、Approved dosing regimen MCI-186

登记的停止原因（原文）：Business objectives have changed.

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

药物 / 成分：Ipilimumab、Nivolumab

登记的停止原因（原文）：Slow accrual, competing studies, and lack of efficacy

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

药物 / 成分：Obeticholic acid、Bezafibrate 200 MG、OCA Placebo、Bezafibrate 200 mg Placebo

登记的停止原因（原文）：Intercept made a business decision to terminate the study based on FDA's request for voluntary withdrawal of Ocaliva and the issuance of clinical hold on studies under US IND involving OCA.

Contribution of Auriculotherapy in the Management of Mastectomy With Immediate Reconstruction by Latissimus Dorsi Flap (ATMAGD)

药物 / 成分：Auriculotherapy、Chronic Post-Surgical Pain evaluation

登记的停止原因（原文）：difficulty of recruitment

Analgesic Ear Drops for Children With Acute Otitis Media

药物 / 成分：lidocaine hydrochloride 5mg/g

登记的停止原因（原文）：Trial accrual problems

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

药物 / 成分：Rocatinlimab、Placebo

登记的停止原因（原文）：Sponsor Decision

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

药物 / 成分：ATG-031

登记的停止原因（原文）：The study was terminated because of sponsor's development strategy change

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

药物 / 成分：Best Supportive Care、Balstilimab、Botensilimab

登记的停止原因（原文）：Pharmaceutical Sponsor discontinued trial financial support

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

药物 / 成分：Hyperpolarized 13C-Pyruvate

登记的停止原因（原文）："Study terminated due to institutional resource constraints, including limited availability of specialized equipment and technical support. Termination was not related to participant safety, data quality, study conduct, or the investigational product

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

药物 / 成分：Paltusotine、Placebo

登记的停止原因（原文）：The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine).

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

药物 / 成分：CodaVax-RSV、Normal Saline

登记的停止原因（原文）：Sponsor Decision

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

药物 / 成分：Paltusotine、Placebo

登记的停止原因（原文）：The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine).

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

药物 / 成分：Filgotinib、Filgotinib

登记的停止原因（原文）：The sponsor decided to stop recruitment and to early terminate the trial with 9 enrolled patients.

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

药物 / 成分：BI 765883、Gemcitabine、Nab-paclitaxel

Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide

药物 / 成分：Hydrochlorothiazide 50mg Tablet、Placebo Tablet

登记的停止原因（原文）：Futility of the study

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

药物 / 成分：BGB-21447

登记的停止原因（原文）：This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.

A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia

药物 / 成分：Nilotinib、Nilotinib、Asciminib

登记的停止原因（原文）：Sponsor decision: The primary endpoint of the core/TF1 was achieved, and the sample size of Extension/TFR2 was unlikely to yield meaningful results. No new safety signals were observed. For these reasons, continuing the study was not justified.